Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-1103 in Methamphetamine Use Disorder
NCT06721494Phase 2Recruiting
- Start
- Feb 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of CS-1103 in methamphetamine use disorder (MUD) and methamphetamine intoxication (2 arms). Primary endpoints: Number of participants with CS-1103-related adverse events at Day 10 and Time course and magnitude of urine excretion of methamphetamine at 48 hours. Started Feb 2026; status: recruiting.
02
Drugs
CS-1103
03
Conditions
methamphetamine use disorder (MUD)methamphetamine intoxication
Beyond the preview
Go deeper on NCT06721494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721494.